More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, accordin…
Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes! In this episode, we dive into the complexities of obesity with gastroenterologist Pooja Singhal. Together, we explore the media’s portrayal of new obesity medication…
At the November 2022 Obesity Week in San Diego, it was clear something big was happening. A late-breaking session released results of the STEP TEENS phase IIIa trial, showing 16 percent weight loss in adolescents with obesity treated with once-weekly s…
According to some academics, in 2019, a ban on junk food advertising across London’s entire public transport network—foods and drinks high in fat and salt and ads for foods–resulted in the prevention of 100,000 obesity cases. Yet the U.S. love af…
As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”
Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes! Join Nisha Kuruvadi, an internal medicine physician, as we explore the intriguing connection between sleep and weight loss. Did you know those precious hours of sleep coul…
Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes! Join us for a conversation with Zachary Fellows, a rheumatologist who spent nearly four years in private practice navigating the complex intersection of obesity and rheuma…
Have you ever heard of a drug called Ozempic? Just kidding. As we all know, this medicine and numerous related drugs are the rage. It is classified as a GLP-1 drug. The percentage of my patients who are taking these drugs is steadily rising. Of course,…
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
On my outpatient clinical rotations last year, I saw ample management of heart disease and smoking cessation counseling. I also saw the annual physicals and checkups. But what surprised me was how many patients were on medications that were just now be…
